ACAnan Chanruang

Anan Chanruang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anan Chanruang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Body Weight and Combined UGT1A1 and NR1I2 Polymorphisms on Dolutegravir Pharmacokinetics Among Thai People Living with HIV: A Population Pharmacokinetic Analysis

    by Anan Chanruang, Angela K. Birnbaum, Sílvia M. Illamola, Sasithorn Sirilun, Suthunya Chupradit, Sasiwimol Ubolyam, Napon Hiranburana, Yong-Soon Cho, Jae-Gook Shin, Anchalee Avihingsanon, et al.

    Background/Objectives: Despite its role as a first-line therapy for Thai people living with HIV (PLWH), dolutegravir (DTG) exhibits significant pharmacokinetic (PK) variability influenced by both genetic and non-genetic factors. This variability may contribute to an increased incidence of neuropsychiatric adverse events (NP-AEs) at the standard 50 mg once daily (OD) dose. Methods: To evaluate the impact of relevant covariates, a population PK model of DTG was developed using 1122 DTG plasma concentrations from 221 Thai PLWH. Monte Carlo simulations were performed to evaluate the probability of target attainment for pre-defined efficacy and safety thresholds across different dosage regimens. Results: Data were analyzed using a one-compartment model with first-order absorption incorporating lag-time, and first-order elimination. Body weight ( 95% of the population but resulted in a substantial proportion (30.46–85.68%) exceeding the safety threshold. In contrast, a reduced dose of 25 mg OD maintained high efficacy target attainment (>80%) while decreasing the proportion exceeding the safety threshold to UGT1A1 and NR1I2 variants.

  • Open Access

    The Association Between Genetic Polymorphisms of UGT1A1, ABCG2, and NR1I2 and Dolutegravir Pharmacokinetic Parameters in Thai People Living with HIV

    by Anan Chanruang, Angela K. Birnbaum, Sasithorn Sirilun, Suthunya Chupradit, Sasiwimol Ubolyam, Napon Hiranburana, Yong Soon Cho, Jae Gook Shin, Anchalee Avihingsanon, Baralee Punyawudho

    Background/Objectives: Dolutegravir (DTG) is recommended as first-line treatment for Thai people living with HIV (PLWH). Real-world studies show high plasma concentration variability, which may increase neuropsychiatric adverse effects. This variability can be influenced by both genetic and nongenetic factors, but data for the Thai population are insufficient. We investigated factors associated with DTG pharmacokinetics in Thai PLWH. Methods: A cross-sectional analysis was conducted in Thai PLWH receiving a 50 mg DTG-based regimen. Intensive blood sampling was performed to determine DTG pharmacokinetic parameters using a non-compartmental analysis. Genotyping for UGT1A1, ABCG2, and NR1I2 was performed. Univariable and multivariable linear regression analyses were used to identify factors associated with DTG pharmacokinetics. Results: A total of 104 Thai PLWH were included. Multivariable analysis demonstrated that both the UGT1A1 poor metabolizer phenotype and body weight were independently associated with DTG exposure. After adjusting for body weight, the UGT1A1 poor metabolizer phenotype was associated with increases of 5.18% in AUC0–24 and 20.59% in Ctrough. No significant association was found between the ABCG2 421 C>A polymorphism and DTG pharmacokinetic parameters. Conclusions: Body weight and the UGT1A1 poor metabolizer phenotype significantly impacted DTG exposure in Thai PLWH. Those with the UGT1A1 poor metabolizer, particularly with lower body weight, had significantly increased DTG exposures. These findings highlight that dose optimization may be worth exploring in selected individuals in this population.